Dr. Hope Rugo reviews practice-changing updates from ESMO 2025 across HER2-positive, triple-negative, and hormone receptor–positive breast cancer, highlighting early-stage results from monarchE and NATALEE, and key findings from the phase 3 evERA Breast Cancer study in the metastatic setting.
